← Leaderboards
Konstantin Petrukhin
Columbia University Health Sciences
$4,542,112
Attributed
$7,659,244
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,659,244 · 8
By mechanism
R01$3,719,451 · 2
R61$1,418,507 · 1
R21$1,270,167 · 4
U01$1,251,119 · 1
Top collaborators
- Christopher L. Cioffi11 shared
- Gennadiy Moiseyev3 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Elizabeth M Bradshaw$11,004,520
- Davangere P Devanand$43,591,695
- Gennadiy Moiseyev$2,581,356
- Christopher L. Cioffi$3,409,772
- Wassim Elyaman$6,169,565
Others in their field
Top investigators on “Specificity”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Eric S Lander · Whitehead Institute For Biomedical Res$527,312,131
- Barton F Haynes · Duke University$483,626,898
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$395,980,920
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$381,706,339
Research focus
SpecificityRetinaBlindnessSmall MoleculeProductionDrug KineticsAtrophicPharmaceutical PreparationsCytotoxicStructure Of Retinal Pigment EpitheliumLipofuscinSerumAge Related Macular DegenerationComplexDosePhotoreceptorsPharmaceutical ChemistryAnimal ModelBlood CirculationDeveloped CountriesBaseAffectMediatingAll-Trans-Retinol
Grant awards (25)
Advancing the small molecule drug candidate with dual specificity as a therapy for dry AMD$644,338
R61 · FY2025 · EY · contact PI
Polypharmacological approach to treatment of Stargardt disease$619,139
R01 · FY2025 · EY · contact PI
Pharmacological modulation of ion currents for treatment of exfoliation glaucoma$205,625
R21 · FY2025 · EY · contact PI
Advancing the small molecule drug candidate with dual specificity as a therapy for dry AMD$774,169
R61 · FY2024 · EY · contact PI
Polypharmacological approach to treatment of Stargardt disease$619,139
R01 · FY2024 · EY · contact PI
Pharmacological modulation of ion currents for treatment of exfoliation glaucoma$262,875
R21 · FY2024 · EY · contact PI
Polypharmacological approach to treatment of Stargardt disease$645,138
R01 · FY2023 · EY · contact PI
Novel therapies for macular degeneration, transthyretin amyloidosis and their common age-related comorbidities$383,990
R01 · FY2022 · EY · contact PI
Pharmacological treatment for atrophic age-related macular degeneration compounded by common forms of age-related amyloid disease$479,015
R01 · FY2020 · EY · contact PI
Pharmacological treatment for atrophic age-related macular degeneration compounded by common forms of age-related amyloid disease$479,015
R01 · FY2019 · EY · contact PI
Pharmacological treatment for atrophic age-related macular degeneration compounded by common forms of age-related amyloid disease$494,015
R01 · FY2018 · EY · contact PI
Pharmacological modulation of thevisual phototransduction cascade for treatment of diabetic retinopathy$200,000
R21 · FY2018 · EY · contact PI
Pharmacological modulation of thevisual phototransduction cascade for treatment of diabetic retinopathy$240,000
R21 · FY2017 · EY · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$201,250
U01 · FY2015 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$201,250
U01 · FY2014 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$75,800
U01 · FY2014 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$71,680
U01 · FY2014 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$201,250
U01 · FY2013 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$201,250
U01 · FY2012 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$49,400
U01 · FY2012 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$47,989
U01 · FY2012 · NS · contact PI
Small molecule drugs for treatment of dry age-related macular degeneration$201,250
U01 · FY2011 · NS · contact PI
Development of the HTS assay for visual cycle inhibitors$160,417
R21 · FY2009 · NS · contact PI
Development of the HTS Assay for Agonists of the Orphan Nuclear Receptor NR2E3$40,250
R21 · FY2009 · NS · contact PI
Development of the HTS Assay for Agonists of the Orphan Nuclear Receptor NR2E3$161,000
R21 · FY2007 · NS · contact PI